Navigation Links
TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
Date:11/12/2008

LA JOLLA, Calif., Nov. 12 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that the Board of Directors has appointed Evelyn Graham as the Company's Chief Executive Officer and as a member of the Company's Board of Directors. Ms. Graham had been serving as the Company's acting Chief Executive Officer since September 1, 2008.

"Ev has done an impressive job as acting CEO in managing the transition of our company and building a platform for the future," said Peter Davis, Chairman of the TorreyPines Board of Directors. "We are delighted that she has agreed to become CEO and a member of the Board at a time when TorreyPines is completing important clinical trials that hold promise for the company's future. With her considerable drug development experience as well as global senior management roles, she has the right mix of skills and experience to successfully lead the Company in meeting its strategic objectives."

"I am excited by this opportunity and look forward to continuing to work with TorreyPines' talented management team and dedicated employees," said Ms. Graham.

Ms. Graham joined TorreyPines in 2004 as Vice President, Development. She was then promoted to Vice President, Corporate Development in 2005, Chief Operating Officer in 2006 and acting Chief Executive Officer in September 2008. Prior to joining TorreyPines Ms. Graham was Executive Director, Development Operations at Purdue Pharma from 2000 to 2003. From 1998 to 2000, she was Senior Vice President of Business Development at Ingenix Pharmaceutical Services, a division of UHG, and served as Vice President of Clinical Operations at Worldwide Clinical Trials, prior to its acquisition by UHG. Previously, Ms. Graham held positions in oper
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
2. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
5. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
6. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
7. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
8. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
11. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... This research report “Biodegradable Plastics Market by ... Cellulose, PCL), by Application (Packaging, Fibers, Agriculture, Injection ... defines and segments the global biodegradable plastics market ... volume and value. , Browse 75 Market Data ... and in-depth TOC on “Biodegradable Plastics Market by ...
(Date:10/25/2014)... Great Barrington, MA (PRWEB) October 25, 2014 ... contamination control products, is pleased to announce the ... to achieve the highest level of contamination containment ... in ISO Class 3 and higher cleanroom environments, ... continuous filament polyester knit laundered wiper that continues ...
(Date:10/25/2014)... Investor-Edge has initiated coverage on ... ), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ), ... Pharmaceuticals Inc. (NASDAQ: PPHM ), and StemCells ... can be accessed at: http://investor-edge.com/register . ... on a positive note as the Dow Jones Industrial ...
(Date:10/22/2014)... , Oct. 22, 2014 Research ... the "Global DNA Diagnostics Market (Product types, ... Share, Global Trends, Company Profiles, Demand, Insights, Analysis, ... 2020" report to their offering. ... (products, applications, techniques, end users and Geography) Global ...
Breaking Biology Technology:Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 2Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 4Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3
... Conn. , April 28 Goodwin Biotechnology Inc., a full ... development services company, jointly announced today their collaborative agreement to create ... services. , , , ... collaboration will enhance and strengthen the clinical development services integrating cDNA ...
... 28 The global biotechnology industry was able to ... financial performance in 2009, with the world,s established biotech centers ... gap between the "haves" and "have nots" in the industry ... companies in accessing the capital needed for R&D. These and ...
... ... of its Global Food, Agribusiness and Biofuels practice, presents findings today from a new ... and Agricultural Infrastructure" at the Land Conference 2010 organized by The World Bank in ... ...
Cached Biology Technology:Goodwin Biotechnology Inc. and Hyprocell LLC Announce Collaboration 2Goodwin Biotechnology Inc. and Hyprocell LLC Announce Collaboration 3Biotech Industry Showing Resilience Despite Challenging Conditions 2Biotech Industry Showing Resilience Despite Challenging Conditions 3Biotech Industry Showing Resilience Despite Challenging Conditions 4Biotech Industry Showing Resilience Despite Challenging Conditions 5Biotech Industry Showing Resilience Despite Challenging Conditions 6Biotech Industry Showing Resilience Despite Challenging Conditions 7Private Sector Investment in Agriculture Emerging as a Significant Alternative Asset Class: New HighQuest Partners Study 2Private Sector Investment in Agriculture Emerging as a Significant Alternative Asset Class: New HighQuest Partners Study 3Private Sector Investment in Agriculture Emerging as a Significant Alternative Asset Class: New HighQuest Partners Study 4
(Date:10/25/2014)... A recent report, "Genetic Testing Market Outlook 2018", provides ... testing market. A comprehensive introduction of gene-based tests, their ... On account of our analysis of the past and ... forecast for genetic testing has been drawn, according to ... CAGR of around 9% during 2013-2018. Our report ...
(Date:10/22/2014)... (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended September 30, 2014. Revenue for the ... 40% compared to $4.3 million in the same quarter last ... $4.1 million compared to $1.0 million in the third quarter ... period was primarily due to: i) a $1.0 million increase ...
(Date:10/17/2014)... is critical and pertinent for practicing physicians and clinicians ... epidemic. The Journal, Disaster Medicine and Public Health ... and Public Health, to surround the public, medical professionals ... moment. , On October 17, the journal published ... primer was prepared by Dr. Eric Toner, internist and ...
Breaking Biology News(10 mins):Genetic Testing Market Outlook 2018 2Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7
... Groundbreaking research led by the U.S. Department of Energy ... time that the signatures of the genes alone in ... of the sampled environments. This study, published in the ... genome sequencing to accelerate advances in environmental sciences akin ...
... throughput microarray analyses result in many differentially expressed ... process of interest. In order to identify biological ... in which pairs of gene names and combinations ... , MEDLINE search strings for 15,621 known genes ...
... Joslin Diabetes Center have found genetic regions that, when defective, ... in a series of mis-steps that lead to type 1 ... journal Immunity, the researchers are now trying to hone in ... patients. , “The significance of this study is that we ...
Cached Biology News:Study reveals new technique for fingerprinting environmental samples 2Study reveals new technique for fingerprinting environmental samples 3Genetic defects give the immune system the green light to attack the pancreas 2Genetic defects give the immune system the green light to attack the pancreas 3
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
... Mouse anti-Cytohesin 2, Monoclonal Antibody, Unconjugated ... assay dependent dilution. ICC: Use at an assay ... 5 - 10 ug/ml, this concentration is determined ... molecular weight: 40 kDa. Not tested in other ...
SHP-2 Antibody...
... Glycine Transporter 2, Neuronal (GLYT2). The ... from the central nervous system. The staining ... pattern described using in situ hybridization with ... has been described for glycinergic neurons. Preabsorption ...
Biology Products: